Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
1978 2
1979 3
1980 2
1982 2
1984 2
1985 5
1986 6
1987 7
1988 5
1989 7
1990 5
1991 7
1992 14
1993 17
1994 17
1995 24
1996 32
1997 32
1998 42
1999 45
2000 54
2001 53
2002 53
2003 71
2004 48
2005 68
2006 92
2007 69
2008 84
2009 88
2010 111
2011 104
2012 92
2013 112
2014 114
2015 107
2016 107
2017 113
2018 113
2019 108
2020 125
2021 121
2022 99
2023 73
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

2,210 results

Results by year

Filters applied: . Clear all
Page 1
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E. Freedman A, et al. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814159 Free article. Review.
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. ...Lenalidom …
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicu …
How I treat posttransplant lymphoproliferative disorder.
Amengual JE, Pro B. Amengual JE, et al. Blood. 2023 Oct 26;142(17):1426-1437. doi: 10.1182/blood.2023020075. Blood. 2023. PMID: 37540819
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). ...
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid orga …
Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.
Atallah-Yunes SA, Salman O, Robertson MJ. Atallah-Yunes SA, et al. Br J Haematol. 2023 May;201(3):383-395. doi: 10.1111/bjh.18763. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36946218 Review.
Post-transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid proliferations that occur as a result of immunosuppression following solid organ transplant (SOT) and haematopoietic stem cell transplant (HSCT) with the majority being driven by …
Post-transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid proliferations that occur as a result o …
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphami …
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( Clinical …
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, de Fijter JW, Rostaing L, Berger SP, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F. Budde K, et al. J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628. Epub 2021 Dec 1. J Am Soc Nephrol. 2021. PMID: 34706967 Free PMC article. Clinical Trial.
METHODS: Stable adult kidney transplant recipients 6-60 months post-transplantation under CNI-based immunosuppression were randomized (1:1) to switch to belatacept or continue treatment with their established CNI. ...One patient in the belatacept group had post-transplant …
METHODS: Stable adult kidney transplant recipients 6-60 months post-transplantation under CNI-based immunosuppression were randomized …
Clinical development of siltuximab.
Davis CC, Shah KS, Lechowicz MJ. Davis CC, et al. Curr Oncol Rep. 2015 Jul;17(7):29. doi: 10.1007/s11912-015-0453-1. Curr Oncol Rep. 2015. PMID: 25986720 Review.
Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in …
Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatme …
Porcine Lymphotropic Herpesviruses (PLHVs) and Xenotranplantation.
Denner J. Denner J. Viruses. 2021 Jun 4;13(6):1072. doi: 10.3390/v13061072. Viruses. 2021. PMID: 34199939 Free PMC article. Review.
Until now, no association between PLHVs and any pig diseases had been described. However, PLHV-1 causes a post-transplantation lymphoproliferative disorder (PTLD) after experimental transplantations in minipigs. ...
Until now, no association between PLHVs and any pig diseases had been described. However, PLHV-1 causes a post-transplantation lymphoprol …
Waldenström's macroglobulinaemia.
Johnson SA, Oscier DG, Leblond V. Johnson SA, et al. Blood Rev. 2002 Sep;16(3):175-84. doi: 10.1016/s0268-960x(02)00016-4. Blood Rev. 2002. PMID: 12163003 Review.
Waldenstrom's macroglobulinaemia (WM) is most usefully defined as a distinct chronic lymphoproliferative disorder with characteristic marrow morphology and phenotype; although nodal morphology if available will reveal a lymphoplasmacytoid lymphoma, the presence of a …
Waldenstrom's macroglobulinaemia (WM) is most usefully defined as a distinct chronic lymphoproliferative disorder with charact …
Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder.
Lee M, Abousaud A, Harkins RA, Marin E, Balasubramani D, Churnetski MC, Peker D, Singh A, Koff JL. Lee M, et al. Curr Oncol Rep. 2023 Aug;25(8):883-895. doi: 10.1007/s11912-023-01418-0. Epub 2023 May 10. Curr Oncol Rep. 2023. PMID: 37162742 Review.
PURPOSE OF REVIEW: A relative lack of molecular and clinical studies compared to other lymphoid cancers has historically made it difficult to determine optimal management approaches in post-transplant lymphoproliferative disorder (PTLD). ...Epstein Barr virus …
PURPOSE OF REVIEW: A relative lack of molecular and clinical studies compared to other lymphoid cancers has historically made it diff …
2,210 results